Where does Regeneron Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Regeneron Pharmaceuticals, Inc. ranks #400 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Regeneron Pharmaceuticals, Inc. hold?

Regeneron Pharmaceuticals, Inc. holds 1,117 US utility patents granted between 2015 and 2025, spanning 61 technology areas.

What is Regeneron Pharmaceuticals, Inc.'s Innovation Score?

Regeneron Pharmaceuticals, Inc. has an Innovation Score of 71.3 out of 100 (top 1% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Regeneron Pharmaceuticals, Inc. focus on?

Regeneron Pharmaceuticals, Inc.'s top technology area is C07K (Peptides) with 824 patents. Grants appear in 61 CPC subclasses total.

Is Regeneron Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Regeneron Pharmaceuticals, Inc.'s recent grant velocity is +77% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Regeneron Pharmaceuticals, Inc.'s patents?

Regeneron Pharmaceuticals, Inc.'s patents average 20.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Regeneron Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Regeneron Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 1,117 granted patents across 61 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Regeneron ranks #400 of 49,997 tracked US assignees by granted-patent volume, with 1,117 patents across 61 technology areas.

#400
of 49,997 US assignees by volume: Top 1%
by Innovation Score (71.3/100): 20.7
avg claims per patent: +77%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R400 · US Corporation #400 · 1,117 grants

GRANTS-LARGE · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-LARGE 1.1K grants
TOP-DECILE #400/49,997
PHOTO-FINISH ASM IP Holding B V
CPC-WIDE C07K · 61 areas
INNOV-STRONG 71.3/100
CLAIMS-DENSE 20.7 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +77% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: ASM IP Holding B.V. (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Contemporary… · near

71
Regeneron Pharmaceut… · this assignee

71
Magna · near

71
Kyocera AVX Components · near

71
Massachusetts… · near

71
3D Lighting… · lowest

7

What this shows Regeneron's Innovation Score is 71.3/100 (top 1% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

How Regeneron's grant cadence moved

Between 2020–2024, Regeneron Pharmaceuticals, Inc. received 630 grants versus 355 in 2015–2019 (+77% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2024 at 163 grants and bottomed in 2015 at 50. Lead class C07K accounts for 73.8% of the portfolio across 61 subclasses. Volume neighbours: Bytedance Inc. (#396) and Synaptics Incorporated (#404).

Regeneron's three-year grant acceleration

From 2019–2021 to 2022–2024, Regeneron Pharmaceuticals, Inc. moved from 296 to 426 grants (1.44x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #490. See the growth leaderboard.

Bytedance

1,130
Cree

1,127
Cornell University

1,126
BSH Hausgeräte

1,122
Regeneron Pharmac… ◀

1,117
ASM IP Holding B V

1,116
Shenzhen China St…

1,116
Marvell Asia PTE

1,108
Synaptics Incorpo…

1,107

What this shows Regeneron holds 1,117 patents at rank #400, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Regeneron

By rank, the assignees closest to #400 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Regeneron's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Regeneron, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (71 here).

Contemporary Amperex Technology Co., Limited 71 Magna Electronics Inc. 71 Massachusetts Institute of Technology 71 Kyocera AVX Components Corporation 71

Similar claim depth

Nearest assignees by average claims per patent (20.7 here).

Ampere Computing LLC 20.7 avg Imagine Communications Corp. 20.7 avg Itron Networked Solutions, Inc. 20.7 avg Infirst Healthcare Limited 20.7 avg

Regeneron's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

71 Top 1% higher than 99% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Regeneron Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	50	4.5%
2016	62	5.6%
2017	77	6.9%
2018	74	6.6%
2019	92	8.2%
2020	93	8.3%
2021	111	9.9%
2022	125	11.2%
2023	138	12.4%
2024	163	14.6%
2025partial year	132	11.8%

Which technologies does Regeneron Pharmaceuticals, Inc. patent most?

C07K - Peptides 824

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 626

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 529

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 458

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 301

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 242

C12Y - Enzymes 103

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 95

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 77

Y02A - Technologies FOR Adaptation TO Climate Change 48

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 41

B01D - Separation 30

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 26

H01J - Electric Discharge Tubes OR Discharge Lamps 23

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 18

Top 15 of 61 technology areas

Where it ranks

Overall rank by patents

#400

of 49,997 tracked assignees

Innovation Score

71.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Regeneron Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Regeneron Pharmaceuticals, Inc.'s lead technology class is C07K (Peptides), 73.8% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #400 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Regeneron Pharmaceuticals, Inc. against Bytedance Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 71.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.